{"filing":{"accession_number":"0001213900-26-088071","cik":"0001584371","ticker":"ICCM","company_name":"IceCure Medical Ltd.","form":"6-K","filing_date":"2026-08-12","report_date":"2026-06-30","primary_document":"ea0301287-6k_icecure.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1584371/000121390026088071/ea0301287-6k_icecure.htm"},"events":[{"id":27079,"run_id":24650,"accession_number":"0001213900-26-088071","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing IceCure's financial results for the first half of 2026, disclosing revenue of $1.8 million (45% year-over-year growth), gross profit of $548,000, and a net loss of $8.775 million. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and cash flows) for the six-month period ended June 30, 2026, along with operational highlights such as 70% growth in active installed base and $8.5 million in capital raised. This is a discrete earnings announcement, not a periodic financial report filing itself.","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28452,"accession_number":"0001213900-26-088071","item_number":"EX-99.3","item_title":"ea030128701ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing IceCure's financial results for the first half of 2026, disclosing revenue of $1.8 million (45% year-over-year growth), gross profit of $548,000, and a net loss of $8.775 million. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and cash flows) for the six-month period ended June 30, 2026, along with operational highlights such as 70% growth in active installed base and $8.5 million in capital raised. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:46:56.944486+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28450,"accession_number":"0001213900-26-088071","item_number":"EX-99.1","item_title":"ea030128701ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim condensed consolidated financial statement for the six-month period ended June 30, 2026, comprising balance sheet, statements of comprehensive loss, changes in shareholders' equity, and cash flows with accompanying notes. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The disclosure is material because it reveals substantial accumulated losses ($129.2M), ongoing negative operating cash flows ($8.1M in H1 2026), and explicit going-concern language in Note 1.B stating \"substantial doubts about the Company's ability to continue as a going concern.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:46:56.944486+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-12"},{"id":28451,"accession_number":"0001213900-26-088071","item_number":"EX-99.2","item_title":"ea030128701ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) of financial condition and results of operations for the six months ended June 30, 2026. It is a periodic interim financial report covering a half-year period, not a discrete event or earnings press release. The document presents comparative financial statements, detailed breakdowns of revenues, operating expenses, and cash flows for the interim period, which is the hallmark of a periodic interim filing rather than an event disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:46:56.944486+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-12"},{"id":28452,"accession_number":"0001213900-26-088071","item_number":"EX-99.3","item_title":"ea030128701ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing IceCure's financial results for the first half of 2026, disclosing revenue of $1.8 million (45% year-over-year growth), gross profit of $548,000, and a net loss of $8.775 million. The exhibit includes condensed consolidated financial statements (balance sheet, income statement, and cash flows) for the six-month period ended June 30, 2026, along with operational highlights such as 70% growth in active installed base and $8.5 million in capital raised. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:46:56.944486+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-12"}]}